Nevertheless, ruxolitinib has also been proven to be effective in Ph-like ALL, a high-risk molecular subtype that has a gene expression profile similar to that of Ph+ ALL but does not harbor the BCR-ABL1 gene fusion. Here, BCR is linked to acute lymphoblastic leukemia.